Introduction

Problem

Solution

Success to Date

PhysiSens’s Rapid Success

  • PhysiSens’s 2020 - 2021 Market Research Study & Validation Study validated the market need.
  • To date, PhysiSens has raised $8,000 in non-equity funding. The Founder was one of the finalists in the Fairfield University StartUp Showcase, winning $3,000. Additionally, PhysiSens was awarded a research and development grant from the University of Bridgeport and CT Next for $5,000. They used the grant to research and develop and prove the viability and feasibility of their proof of concept.
  • PhysiSens was one of 12 companies that was accepted into the Accelerator for Biosciences in Connecticut (ABCT) for the 2021 cohort. The company was recognized for leveraging, innovating, and pioneering multiple unique technologies to help solve the complex challenges of telerehabilitation.
  • During their time at ABCT, PhysiSens made key connections with major hospitals and healthcare professionals to even further de-risk and validate the product.
  • Proof of concept prototype created.
  • Two Provisional Patents focusing on their innovative sensor systems and software technology using patent support from Wiggin and Dana LLP.
  • PhysiSens is initiating an exceptionally strong, strategic patent portfolio, planning to file nine additional patent applications for their innovative technologies over the next few years.

Market

The Team:

Winston DeMartini
Founder & CEO
Winston DeMartini is the founder & CEO of PhysiSens. He is a graduate of Fairfield University, with a degree in marketing and management. Winston’s background is in user interface/user experience design, technology, marketing, and management. He is connected with a plethora of physical therapists, hospitals, digital health companies, professional and college sport managers and players, fitness enthusiasts, and others that provide valuable feedback on the product and its applicability in various markets. Winston was a winner of the Fairfield StartUp competition and is now an advisor to the program. Additionally, Winston led the company through the Accelerator for Biosciences in Connecticut (ABCT) where he made key contacts with hospitals and healthcare professionals to de-risk and validate the product idea. PhysiSens was one of 12 companies that was accepted into ABCT’s 2021 cohort, and it was recognized for leveraging and advancing two unique technologies to help solve the complex challenges of telerehabilitation.

Advisory Board

The Founder of PhysiSens has created a high caliber advisory board to help lead PhysiSens, including serial entrepreneurs, C-Suite executives, vetted technology professionals, and adept financial executives:

Matus Knoblich
Advisor
Matus Knoblich, an Advisor to PhysiSens, is the CEO of Glo-Med Networks Inc. He has a global perspective across various and differentiated industries/sectors, with a primary focus on healthcare going back over 20 years. Having conducted business all over the world along with expat experiences, he is currently the CEO of multiple healthcare focused businesses in medical device servicing, sales, distribution, warehousing and logistics. Understanding ever changing business climates, Matus has expanded his business portfolio across multiple healthcare sectors, vertically integrating and expanding to mitigate risk. He is also an active investor in multiple medical technology startups throughout the world, bringing innovative and next generation ideas and products from early conceptual phases all the way through R&D into commercialization and distribution. Matus has put a heavy emphasis on personalized customer service, driving sharing of industry knowledge and advancement through proper networking and communication across various healthcare platforms and networks.
Jeffery Hendrickson
Advisor
Jeffery Hendrickson, an Advisor to PhysiSens, is a private equity operating and senior corporate leader who is practiced in leading B2B, B2C and light industrial businesses with innovative, differentiating, value-added service components. Jeff specializes in Acquisition identification, due diligence, hands-on leadership and team building. He was the president and COO of Velocity Express, CEO and Managing Director of Sports & Health Clubs, VP of Budget Rent a Car, VP of Brink’s, and VP of National Car Rental. He is also a member of the Executive Forum angel investment group. Jeff is instrumental to PhysiSens, connecting them to a plethora of key connections, while guiding the company on their value added components, innovation / competitive differentiation, and their strategic positioning within the market.
Christopher Huntley
Advisor
Christopher Huntley, an Advisor to PhysiSens, is an Associate Professor of Information Systems and Operations Management at Fairfield University, in the Dolan School of Business. Additionally, Chris is the Director of Entrepreneurship at Fairfield University, including the nationally recognized Fairfield StartUp program. He is an experienced program director and department chair with a demonstrated history of academic leadership. Currently teaching Big Data classes in the graduate Business Analytics program and shepherding the Fairfield StartUp entrepreneurship program. Chris is a significant asset to PhysiSens due to his exceptionally accomplished background in academia, specifically his technical knowledge of big data, data analytics, and software, as well as his experience mentoring start-ups.
Noreen Harrington
Advisor
Noreen Harrington, an Advisor to PhysiSens, is the President and board member of DataWhys, a technology company using Interpretable Artificial Intelligence in Banking & Insurance, Manufacturing, Healthcare and Retail. Noreen brings both management and financial experience to DataWhys as she’s embarking on changing the way they work with new technologies. Previously, she was the head of Fixed Income trading globally for Barclay’s Capital, reporting to the CEO and a member of the Management Committee. Additionally, Noreen was a managing director at Goldman Sachs, in trading, sales and the hedge fund business, in both New York and London. In addition, Noreen is a founder of 85 Broads women's network, now known as Ellevate Network, and she is an angel investor with the group 100 Women In Finance. Noreen is PhysiSens's Financial Advisor.

Business Model

Customer Acquisition, Pipeline, and Commercialization Partners:

PhysiSens has accumulated immense interest in their innovative technology from a plethora of large potential customers and potential commercialization partners, these companies include:

  1. Large digital health company
  2. Large, prestigious hospital
  3. Professional / Major League sports General Manager
  4. College sports team
  5. Medical divisions of the Department of Defense (DOD)

These potential future customers and commercialization partners plan on potentially licensing, testing, and/or partnering with PhysiSens in the future when the product becomes available.

The $500k raised from this round will allow PhysiSens to complete their technological research and development, produce market ready prototypes, and begin testing and licensing their innovative technology and software with their potential customers.

Use of Proceeds


If the offering's maximum amount of $500,000 is raised:

UseValue% of Proceeds
Compensation For Managers$15,0003.0%
Employees / R&D$420,00084.0%
Regulatory / FDA$20,0004.0%
Intellectual Property$20,5004.1%
Intermediary fees$24,5004.9%

Terms

This is an offering of Class A membership unit, under registration exemption 4(a)(6), in PhysiSens LLC. This offering must raise at least $10,000 by July 31, 2024 at 11:59pm ET. If this offering doesn’t reach its target, then your money will be refunded. PhysiSens may issue additional securities to raise up to $500,000, the offering’s maximum.

If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:

3,470,000 units
×
$1 per unit
$3,470,000implied valuation

Financials

These financial statements have been reviewed by an independent Certified Public Accountant.

SEC Filings

The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.

We’re also required to share links to each of the SEC filings related to this offering with investors.

Understand the Risks

Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.

Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.

The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

More Info

Updates

  • May 30, 2024
  • Apr 25, 2024
    Our Founder Winston DeMartini pitched to...

    Our Founder Winston DeMartini pitched to members of the Angel Investor Forum this week. The event was offered by the Accelerator of Biosciences in Connecticut, it was invitation only to alumni of the accelerator program!

  • Apr 2, 2024
  • Mar 25, 2024
    PhysiSens is very excited to announce that we...

    PhysiSens is very excited to announce that we just reached over $18,000 and we are only $7,000 away from achieving our 25k milestone!

    Why is 25k a large milestone? Once we hit $25k, we can begin the Research & Development on our innovative algorithms and software technology. This is extremely exciting, once we begin the prototype software development, we will be able to begin testing and licensing our novel technology with our future customers. This is a huge step for PhysiSens and It will allow us to rapidly progress with the company and raise.

    Our goal is to raise $7,000 to reach $25,000 by this Monday April 1st , and begin the R&D process for our innovative software technology!

    Help us reach our goal and accelerate our progress! Invest in our groundbreaking technology today to reach $25,000 by April 1st!

    Founder CEO, Winston DeMartini

  • Mar 25, 2024
  • Mar 21, 2024
    PhysiSens conducted a research study;...

    PhysiSens conducted a research study; Evaluating Commercial Need for Innovative Technologies in Telerehabilitation Physiotherapy.

    Research Study Findings Concluded:

    1. Physical Therapists find it very difficult to monitor patients and their progress remotely.

    2. Current technologies offered are suboptimal due to a lack of patient data, they want our comprehensive solution for monitoring patients remotely.

    3. Additionally, current devices are uncomfortable to the user, inhibit natural kinematic motions, resulting in incorrect form and an unnecessary increase in injury risk.

    4. Incomplete and inaccurate virtual information delay patients’ recovery and increase patients’ re-injury potential.

    5. Patients are not effective at communicating, resulting in skipping exercises all together and prolonging recovery and increasing risk potential to setback and injury.

    6. Therapists want to use our technology to solve the above pain points, by providing data driven, evidence based treatment.

  • Mar 17, 2024
    Customer Acquisition, Pipeline, and...

    Customer Acquisition, Pipeline, and Commercialization Partners

    PhysiSens has accumulated immense interest in their groundbreaking sensor and software technology from a plethora of large potential customers and potential commercialization partners.

    Our future customers that want to test and license our product include: Large digital health company Large prestigious hospital Professional / Major League sports General Manager College sports team Medical divisions of the Department of Defense (DOD)

    These future customers and commercialization partners plan on licensing, testing, and/or partnering with PhysiSens in the future when the product becomes available.

    The $500k raised from this round will allow us to complete our technological research and development, produce market ready prototypes, and begin testing and licensing our groundbreaking SmartShirt and A.I. Software technology with these potential customers.

    Invest In Us Today To Accelerate Our Progress! Onwards and Upwards!

  • Mar 16, 2024
    The delivery of remote therapy results in...

    The delivery of remote therapy results in challenges for physical therapists to accurately assess, track, and evaluate patients’ progress in a virtual telerehabilitation setting because they are not with the patient to monitor exercises and biomechanics.

    Our patent pending technological sensor and software innovations are groundbreaking in adding value to our physical therapist customers. Providing therapists with full complete data sets to leverage their diagnostic skills in order to aid in quantifying patients’ recovery process, prescription of treatment, exercise selection, and helping to decrease patients’ recovery time and reinjury risks.

    This will be accomplished through our groundbreaking technological advancements in our user-friendly, clinically viable sensor and A.I. M.L. software technologies. We are providing full complete data sets to physical therapists allowing them to use an evidenced based data driven approach to physical therapy recovery.

    Invest today In Our Tech

  • Mar 9, 2024
    Did You Know That PhysiSens Has A Huge Market...

    Did You Know That PhysiSens Has A Huge Market Opportunity:

    PhysiSens is in the massive physiotherapy market. US physical therapy market: $46.44 Billion (2020) and expected to grow to $71.75 Billion (2028). On top of this, the Telerehabilitation market in North America was valued at $1.12 Billion (2019) with a CAGR of 13.4%. We are specifically targeting large hospitals, physical therapy chains, and digital health companies to commercialize our product on a large scale.

    Our secondary market is Professional and College Sports, worth 51.1 Billion, DOD Military Wearable market in the U.S. worth $1.5 Billion (2022), Mass Consumer Fitness Wearable Market size in the U.S. $39.5 Billion (2022) -> growing to $187.2 Billion (2032), and Personal Protective Equipment (PPE) market in North America is $26.99 Billion (2022) -> growing to $38.15 Billion (2029).

    Total market size today (2024) adds up to $165.53 Billion. Total market size in the future (2028+) projected at $349.70 Billion.

  • Mar 6, 2024
    PhysiSens is very excited to announce that we...

    PhysiSens is very excited to announce that we just hit $10,100 on Netcapital! This is a huge milestone for PhysiSens, as it will allow us to begin our Research and Development on our SmartSleeve market viable prototype! The company extends a big thank you to all the early investors!

    It’s extremely exciting to begin the SmartSleeve prototype development, speeding up the timeline to begin testing the SmartSleeve with physical therapists.

    While reaching this milestone will allow us to initiate the R&D process, we will still need more capital to create a finished, user-friendly product. As a result, our next milestone goal in this Netcapital raise is to reach $25,000 so we can create our innovative software technology to pair with our newly created SmartSleeve prototype. The planned software technology will showcase the novel features of the SmartSleeve, allowing physical therapists and investors to see the tremendous market potential of this product!

    Founder CEO, Winston DeMartini

  • Jan 26, 2024
    Primary offering of 500,000 units at $1
  • Jan 26, 2024

Ask a Question

Proofread your comment before submitting: once it's posted, you can’t edit or delete it. Investors are advised to review our Discussion Board Policy before submitting a comment. For the fastest help with the web site, email help@netcapital.com instead of commenting.

Looking to raise capital?
We can help turn your friends, family and customers into investors.

Learn more

Interested in more investment opportunities?
Browse all offerings currently available.

See more